PRMT1 loss sensitizes cells to PRMT5 inhibition-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

PRMT1 loss sensitizes cells to PRMT5 inhibition

Published:2019-03-27 Issue:10 Volume:47 Page:5038-5048
ISSN:0305-1048
Container-title:Nucleic Acids Research
language:en
Short-container-title:

Author:

Gao Guozhen¹,Zhang Liang¹,Villarreal Oscar D¹,He Wei¹,Su Dan²,Bedford Ella¹,Moh Phoebe¹,Shen Jianjun¹,Shi Xiaobing³,Bedford Mark T¹,Xu Han¹

Affiliation:

1. Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Smithville, TX 78957, USA

2. Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

3. Center for Epigenetics, Van Andel Research Institute, Grand Rapids, MI 49503, USA

Funder

National Institutes of Health

Cancer Prevention and Research Institute of Texas

Publisher

Oxford University Press (OUP)

Subject

Genetics

Link

http://academic.oup.com/nar/article-pdf/47/10/5038/28761888/gkz200.pdf

Reference60 articles.

1. Loss of the major Type I arginine methyltransferase PRMT1 causes substrate scavenging by other PRMTs;Dhar;Sci. Rep.,2013

2. Protein arginine methyltransferases and cancer;Yang;Nat. Rev. Cancer,2013

3. Protein arginine methylation in mammals: who, what, and why;Bedford;Mol. Cell,2009

4. PRMT9 is a type II methyltransferase that methylates the splicing factor SAP145;Yang;Nat. Commun.,2015

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibition of PRMT5 moderately suppresses prostate cancer growth in vivo but enhances its response to immunotherapy;Cancer Letters;2024-10

2. A chemical screen identifies PRMT5 as a therapeutic vulnerability for paclitaxel-resistant triple-negative breast cancer;Cell Chemical Biology;2024-09

3. Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment;2024-07-17

4. Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment;2024-07-17

5. Towards the Targeted Protein Degradation of PRMT1;ChemMedChem;2024-06-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3